Cardiac Allograft Vasculopathy Clinical Trial
Official title:
(RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients
Verified date | May 2019 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Is real-time myocardial perfusion echocardiography (RTMPE) a feasible and effective non-invasive method to detect significant Coronary Allograft Vasculopathy in pediatric and adult cardiac transplant recipients? Will perfusion deficits correlate with significant coronary artery stenosis identified by standard stress echocardiography and Invasive Coronary Angiography (ICA), and identify diffuse small vessel disease more effectively than current non-invasive techniques?
Status | Completed |
Enrollment | 36 |
Est. completion date | June 30, 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year and older |
Eligibility |
Inclusion: - Cardiac transplant recipients (> or equal to 10 months post transplant) - Clinically followed at Mayo Clinic, Rochester Minnesota Exclusion: - Standard contraindications to the use of ultrasound contrast and pharmacologic stress - Recent (< 3 months) hospitalization for heart failure, acute coronary syndrome or allograft rejection - Multi-organ transplant Known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts - Hypersensitivity to perflutren |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | University of Calgary |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With a Perfusion Defect | A perfusion defect will first be identified using clinically indicated invasive coronary angiography (ICA). The presence of a perfusion defect will then be identified using non-invasive real time myocardial perfusion echocardiography (RTMPE). | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01848301 -
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
|
Phase 1 | |
Terminated |
NCT01278745 -
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
|
Phase 2 | |
Withdrawn |
NCT01812434 -
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
|
N/A | |
Withdrawn |
NCT01305382 -
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
|
N/A | |
Recruiting |
NCT05826444 -
Microvascular Cardiac Allograft Vasculopathy Trial
|
||
Suspended |
NCT05756088 -
Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
|
||
Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
Withdrawn |
NCT01157949 -
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
|
Phase 3 | |
Withdrawn |
NCT01305395 -
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
|
N/A | |
Enrolling by invitation |
NCT06147271 -
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT04193306 -
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT02798731 -
Physiologic Assessment of Microvascular Function in Heart Transplant Patients
|
||
Withdrawn |
NCT02777255 -
Severe CAV MRI in Heart Transplant Recipient
|
N/A | |
Completed |
NCT05373108 -
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
|
Phase 4 | |
Withdrawn |
NCT01424917 -
Noninvasive Predictors of Transplant Vasculopathy
|
N/A | |
Recruiting |
NCT04770012 -
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT01078363 -
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
|
N/A | |
Completed |
NCT03734211 -
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
|
Phase 3 | |
Recruiting |
NCT06089486 -
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
|
N/A | |
Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 |